These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1725909)

  • 1. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
    Fleckenstein-Grün G; Frey M; Thimm F; Luley C; Czirfusz A; Fleckenstein A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S1-9. PubMed ID: 1725909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
    Fleckenstein-Grün G; Fleckenstein A
    Ann Med; 1991; 23(5):589-99. PubMed ID: 1756029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Fortschr Med; 1984 Jul; 102(27-28):713-7. PubMed ID: 6479813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excessive mural calcium overload--a predominant causal factor in the development of stenosing coronary plaques in humans.
    Fleckenstein A; Frey M; Thimm F; Fleckenstein-Grün G
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1005-13. PubMed ID: 2076386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats.
    Fleckenstein-Grün G; Thimm F; Frey M; Matyas S
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):207-13. PubMed ID: 7475044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Hofgärtner W; Fleckenstein A
    Drugs; 1992; 44 Suppl 1():23-30. PubMed ID: 1283581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological basis for use of calcium antagonists in hypertension.
    Scriabine A; Kazda S
    Magnesium; 1989; 8(5-6):253-65. PubMed ID: 2693846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calcium antagonists vs ACE inhibitors in the treatment of essential arterial hypertension in the aged].
    Cellamare G; Poppa E; Sgobba G; Bianco G
    Minerva Cardioangiol; 1989 Mar; 37(3):111-8. PubMed ID: 2546102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
    Hof RP; Rüegg UT
    Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical aspects of parathyroid hypertensive factor.
    Lewanczuk RZ; Resnick LM; Ho MS; Benishin CG; Shan J; Pang PK
    J Hypertens Suppl; 1994 Jan; 12(1):S11-6. PubMed ID: 8207559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Modification of coronary arteriosclerosis in man by calcium antagonists?].
    Schneider W; Roebruck P; Cieslinski G; Noack H; Kober G; Alle M; Kaltenbach M
    Z Kardiol; 1991; 80 Suppl 9():63-71. PubMed ID: 1796651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker.
    Chatelain P; Mouton J; Feys G; Laruel A; Manning AS
    Cardiovasc Res; 1995 Dec; 30(6):1038-43. PubMed ID: 8746222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental arteriosclerosis in Rhesus monkeys induced by multiple risk factors: cholesterol, vitamin D, and nictotine.
    Liu LB; Taylor CB; Peng SK; Mikkelson B
    Paroi Arterielle; 1979 Apr; 5(1):25-37. PubMed ID: 114963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium antagonists and atherosclerosis.
    Betz E; Weiss HD; Heinle H; Fotev Z
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S71-5. PubMed ID: 1725009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiatherosclerotic effects of calcium antagonists.
    Paoletti R; Bernini F; Corsini A; Soma MR
    J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S6-10. PubMed ID: 8852538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.